1.7 Million Dollar Grant Towards Development of Theratechnologies’ Targeted Oncology Platform

Oct 04, 2019
PDF Version
Supporting Materials:

Montreal, Canada – October 4, 2019 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that the Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute to a grant totaling 1.7 million dollars to l’Université du Québec à Montréal (UQAM) as part of the overall investment made by Theratechnologies towards the development of its targeted oncology platform.

The funds have been earmarked for work conducted by Dr Borhane Annabi at the Molecular Oncology Laboratory of the UQAM. Dr Annabi and his team will focus their efforts on the development of the targeted oncology platform in triple-negative breast cancer.